Hints and tips:
Related Special Reports
...Weber is a paid consultant for Merck and Moderna....
...The US drugmaker has spent almost $30bn on acquisitions over the past two years, snapping up Arena Pharmaceuticals, Biohaven Pharmaceuticals, Global Blood Therapeutics, ReViral and Trillium Therapeutics....
...Rivals AstraZeneca, Johnson & Johnson, Russia’s Sputnik V and new entrants such as Novavax make up the remainder of the market, which is forecast to double in value to $124bn next year....
...“Africa is a key market for Sputnik V,” said the Russian Direct Investment Fund, a Kremlin-run wealth fund overseeing Sputnik V’s foreign sales....
...After such strong reads from the first two releases (three if we count Russia’s Sputnik V), the disappointing AZN figures were perhaps bound to prompt downward pressure on the company’s shares....
...In August, Russia became the first country to approve a Covid-19 vaccine — named Sputnik V — for civilian use, but western experts cast doubt on its efficacy and safety....
...If there is a sense from this earnings season that confidence in a V-shaped recovery for profits is misplaced, then the impact will probably be hardest on companies with weak balance sheets, and on those...
...Beyond these three biotechs, Crispr could end up transforming the entire pharmaceutical industry....
...Their concentrated ownership of industries such as airlines and pharmaceuticals may push up travel and drug prices, some academics argue....
...Some, such as Christophe Weber at Takeda Pharmaceutical and Sarah Casanova at McDonald’s Japan, are regarded as successful....
...Christophe Weber is racing to win backing for Japan’s largest-ever outbound takeover, which would catapult the Osaka-based drugmaker into the ranks of the world’s biggest pharmaceutical companies....
...She worked as a janitorial supervisor at C&W client Lonza, a Swiss pharmaceuticals group, which has a production facility in Portsmouth, New Hampshire....
...Investors say Pfizer is in much better shape than when he took the top job in 2010, shortly after the company had completed the ill-fated acquisition of Wyeth for $68bn....
...Allegiants underlie Takeda confidence As Christophe Weber, the chief executive of Takeda Pharmaceutical, met with US investors last week, he was brimming with confidence that he would win the requisite...
...If completed, it would rank as one of the industry’s biggest, and mark a significant moment in the evolution of Japan Inc as a global dealmaker....
...Mitsuo Sawai, president of Sawai Pharmaceutical, is one such chief executive....
...He places human embryonic and pluripotent stem cells — that have the potential to grow into nearly every cell of the body — in tiny ‘U’ or ‘V’ shaped dishes in the lab to grow them into different types of...
...Pharmaceutical groups, which might see similar benefits from quantum technology in the long term, are still on the sidelines....
...The current version, mostly acquired with Wyeth in 2009, includes brands such as Centrum supplements and ChapStick....
...But it subsequently took on a new portfolio when it acquired Wyeth in 2010....
...Thanks to a series of court rulings since the mid-2000s, such as eBay v MercExchange in 2007, Mayo Collaborative Services v Prometheus Laboratories in 2012 and Alice Corp v CLS Bank in 2014, and the subsequent...
...the neuroscience business should not “shock investors but is likely to raise a debate over possible use of proceeds should any cash be generated and management of any earnings dilution [ie deleveraging v...
...A 2009 Supreme Court case involving prescription drug labels, Wyeth v Levine, greenlighted state laws that are stricter than federal laws....
...A Louisiana doctor who has brought a series of whistleblower lawsuits against pharmaceuticals companies is in line for a windfall from Pfizer that would take his total payout from fraud settlements close...
...Martoma had obtained non-public information about an experimental drug for Alzheimer’s that was being developed by listed companies Elan and Wyeth....
International Edition